Share Name Share Symbol Market Type Share ISIN Share Description
Sareum Holdings LSE:SAR London Ordinary Share GB00B02RFS12 ORD 0.025P
  Price Change % Change Share Price Shares Traded Last Trade
  +0.00p +0.00% 0.80p 650,788 08:00:00
Bid Price Offer Price High Price Low Price Open Price
0.75p 0.85p 0.80p 0.80p 0.80p
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology -1.72 -0.05 22.0

Sareum (SAR) Latest News

More Sareum News
Sareum Takeover Rumours

Sareum (SAR) Share Charts

1 Year Sareum Chart

1 Year Sareum Chart

1 Month Sareum Chart

1 Month Sareum Chart

Intraday Sareum Chart

Intraday Sareum Chart

Sareum (SAR) Discussions and Chat

Sareum Forums and Chat

Date Time Title Posts
22/10/201810:53Sareum 2015 2,793
22/8/201719:18Sareum 2016722
12/12/201612:19SAR Sareum Drug Discovery Co.15,853
26/4/201618:292012 Sareum Unleashed4,546
20/4/201609:23SAR news is on its way. fasten your seatbelts!172

Add a New Thread

Sareum (SAR) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
08:51:280.7757,882446.27O
08:37:060.83467,3103,878.67O
08:01:400.77104,362803.59O
07:05:560.7721,234163.50O
2018-10-22 15:37:450.80500,0004,000.00O
View all Sareum trades in real-time

Sareum (SAR) Top Chat Posts

DateSubject
23/10/2018
09:20
Sareum Daily Update: Sareum Holdings is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker SAR. The last closing price for Sareum was 0.80p.
Sareum Holdings has a 4 week average price of 0.73p and a 12 week average price of 0.73p.
The 1 year high share price is 1.03p while the 1 year low share price is currently 0.70p.
There are currently 2,745,223,988 shares in issue and the average daily traded volume is 2,000,817 shares. The market capitalisation of Sareum Holdings is £21,961,791.90.
01/10/2018
20:57
cerrito: For me nothing new and share price reaction justified. I am rather mystified about the news management, First they say mid October and then they bring it forward to October 1 but do not give us audited figures. I have never seen a release of full year figures without them being audited. I do of course appreciate in this case very unlikely there will be any changes with the figures once audited and many people not too bothered…given the simplicity of their financials I would have thought they could have had an audit done in a month. I guess given their situation they had no alternative but to word the going concern statement the way they did. I am assuming that Aurora will have little if any value given they would have told us if they had sorted the toxicology issue. One thing that did strike me in their very good description of the state of play of the programmes was the clear explanation of what is happening commercially with the other TYK2 programmes-I mention this because in the past at AGM’s Tim has been surprisingly vague as to the commercial deals other programmes similar to SAR’S have been struck, Interested to see that R&D expenditure in the year was £1037k not all that much bigger than the £1002k in FY16/17 and indeed £927k in FY 15/16 when they had the full year CHK1 expenses, I do not understand given the modest increase in R&D expenditure why the tax credit has gone up so much, I also see non R&D admin expenses went up from £443kto £674k-when we get the AR we can see how much of this was due to Director salaries. I do not anticipate spending much time on this and await for news-the Sierra quarterlies, equity raises and/or license deals and less important the SAR AR,
26/9/2018
08:14
nobbygnome: Sadly nothing gets the SAR price going like in the good old days. This is good news but of no great value significance because it is so far from the clinic and from being licensed. Nevertheless, previously it would have provoked a spike..... Ho hum....
28/3/2018
13:27
jaknife: What complete twaddle Walter Walcarpets, If current shareholders hang around then, at best, they can expect another tiny milestone payment that will go nowhere to covering the annual costs. The last payment was a mere tiny $0.5m: see: Https://www.investegate.co.uk/sareum-holdings-plc--sar-/rns/milestone-payment-from-chk1-licence-agreement/201701091205026485T/ On the other hand SAR is burning £1.5m to £2m a year which is money wasted on keeping the directors fat. They were forced into a placing last November at a mere 0.7p to make sure that there was adequate capital so that they were still a going concern and exactly the same rules will force them to place again this year. SAR is now in terminal decline. The current market cap of £21m is vastly in excess of the real value of the company which is essentially as a cash shell with a potential contingent asset that might one day yield small pathetic dribbles of cash. If the share price fell 90% then it might just be the right price. JakNife
27/3/2018
11:02
jaknife: Why do you have to come up with such convoluted cr@p to explain why the share price is falling? The share price is down because the company is a pile of poo that's repeatedly failed to deliver, is running low on cash (yet again) and thus shareholders are selling. The only people buying are those with some sort of religious fascination with Sareum.
28/2/2018
23:30
pwhite73: When evaluating AIM companies you must learn to divorce the operational side from the AIM listing. You have no investment in the operational side only the listing. http://www.sareum.com/investors/aim-rule-26/ Click on Shares If you click on the above link it tells you how much of the shares are not in public hands. Only 3.2%. This is one of the worst records on the AIM if the information displayed is correct. Furthermore there are no significant shareholders meaning shareholders holding 3% or more. Go through Sareum's RNS's and you will see there are no holdings RNS. Why? The shares are listed for the sole purpose of funding the company. Special Resolutions at each AGM lifts the limit on how many shares the directors can issue. Because all the shares are in the hands of PIs it means technically the company cannot be taken over. Who would a bidder approach YOU?. Sareum share price will move up and down according to PI sentiment and BB gossip. The shares bear no relation whatsoever to the operational progress the company is clearly making. Sareum's 2.7 billion shares at 0.9p are junk. This is not true of the company.
26/2/2018
16:24
cerrito: I note that SRA's share price did not move over last week and is essentially flat today so it seems the market there not getting too excited about this week's news flow
14/12/2017
09:46
spacedust: 2018 could see more placings. Bring on February for a 400% rise before the ola ings followed by consolidation = death of share price
20/10/2017
10:35
jaknife: spacedust, I think that SAR is overvalued. Simples. I am therefore short. Simples. People buying shares today are effectively paying £25m to buy a piggybank with £2.3m in and the possibility that the company might magic more cash out of thin air in the future. Looking back the company has churned out losses every year apart from this year when it has received a special one-off non-recurring lump sum. Next year it's going to make a loss and some of that cash will disappear, hence this time next year it will be a piggbank with, say ,only £1.3m in. Buying shares in Sareum is bonkers, they're worth 10% of the current share price and this time next year they'll be worth even less. SELL JakNife
19/10/2017
15:33
jaknife: Are we all reading the same results? 2.75 billion shares in issue share price 0.925p Market cap £25.4m So the market values the company at over £25m but if you look inside the box it's got less than a tenth of that number in cash. The income this year is a lump sum one-off and losses are to be expected for future years. The share price should fall 90% really.
11/10/2017
12:59
cerrito: I see that Sierra making another presentation and have been rewarded with their share price at a one year high. I am assuming that the recent increase in SAR’s price and trading volumes have been as a result of SRA’s increased profile. We will have the prelims in 2/3 weeks time-I need to say I would be pleasantly surprised if there has been a meaningful advance on Aurora and do not know what to expect on the two TYK programmes Sierra Oncology to Present at the 2017 BIO Investor Forum - "Beyond PARP - Next Generation DDR Therapeutics" scheduled for 11:00 am PT on October 17, 2017 - VANCOUVER, Oct 11, 2017 /CNW/ - Sierra Oncology, Inc. (NASDAQ: SRRA), a clinical stage drug development company focused on advancing next generation DNA Damage Response (DDR) therapeutics for the treatment of patients with cancer, today announced that Dr. Nick Glover, President and Chief Executive Officer, will present an overview of the company entitled "Beyond PARP – Next Generation DDR Therapeutics" at the 2017 BIO Investor Forum in San Francisco. The presentation is scheduled for 11:00 am PT on Tuesday, October 17th. A live audio webcast and archive of the presentation will be accessible through www.sierraoncology.com
Sareum share price data is direct from the London Stock Exchange
add chat code
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:40 V: D:20181023 11:47:14